Osnat Hakimi

Dr. Osnat Hakimi currently serves as an Associate at aMoon Fund, a venture capital firm where she specializes in evaluating emerging biotechnology trends and artificial intelligence applications in healthcare. In her investment role, she analyzes AI-driven drug discovery engines and assesses the commercial viability of clinical platforms developed by companies such as Owkin and Verge Genomics. Hakimi recently co-authored a comprehensive investor analysis following the ASCO 2024 conference, systematically reviewing 190 clinical assets to evaluate new developments in oncology therapeutics and antibody-drug conjugates. Her sector research frequently covers the broader intersection of computational technology and molecular biology, tracking strategic advancements and infrastructure partnerships involving major industry players like Nvidia. As a PhD holder, Hakimi focuses her current professional efforts on identifying scalable biotech innovations and evaluating the technical viability of novel resistance mechanisms in early-stage drug development.